AR051698A1 - Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa - Google Patents
Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasaInfo
- Publication number
- AR051698A1 AR051698A1 ARP050105071A ARP050105071A AR051698A1 AR 051698 A1 AR051698 A1 AR 051698A1 AR P050105071 A ARP050105071 A AR P050105071A AR P050105071 A ARP050105071 A AR P050105071A AR 051698 A1 AR051698 A1 AR 051698A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- optionally substituted
- incorporates
- optionally
- Prior art date
Links
- 229940122159 Myeloperoxidase inhibitor Drugs 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- INLMYVZKXJLFNR-UHFFFAOYSA-N 1,5-dihydropyrrolo[3,2-d]pyrimidine-2,4-dithione Chemical compound SC1=NC(S)=C2NC=CC2=N1 INLMYVZKXJLFNR-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 abstract 1
- 101000909628 Homo sapiens Transcription factor COE3 Proteins 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 102100024200 Transcription factor COE3 Human genes 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Junto con procesos para su preparacion, composiciones que ,los contienen y su uso terapéutico. Los compuesto son inhibidores de la enzima MPO y, por ello, son particularmente utiles en el tratamiento o la prevencion de trastornos neuroinflamatorios, trastornos cardiovasculares. Reivindicacion 1: Un compuesto de la formula (1) donde al menos uno de X e Y representa S y el otro representa O o S; L representa un enlace directo o alquileno C1-7, donde dicho alquileno incorpora opcionalmente un heteroátomo seleccionado de O, S(O)n y NR6 y dicho alquileno incorpora opcionalmente 1 o 2 enlaces dobles C-C, y dicho alquileno está opcionalmente sustituido con uno o varios sustituyentes seleccionados, de modo independiente, de OH, halogeno, CN y NR4R5, alquilo C1-6 y alcoxi C1-6, donde dicho alcoxi incorpora opcionalmente un carbonilo adyacente al O; n representa un numero entero 0, 1, o 2; R1 representa H o i) un anillo saturado o parcialmente insaturado de 3 a 7 miembros que opcionalmente incorpora 1 o 2 heteroátomos seleccionados, de modo independiente, de O, N y S, y que opcionalmente incorpora un grupo carbonilo, opcionalmente sustituido con 1 o varios sustituyentes seleccionados de halogeno, SO2R9, SO2NR9R10, OH, alquilo C1-7, alcoxi C1-7, CN, CONR2R3, NR2COR3 y COE3, donde dicho alcoxi está también opcionalmente sustituido con alcoxi C1-6 y donde dicho alcoxi incorpora opcionalmente un carbonilo adyacente al O y dicho alquilo está también opcionalmente sustituido con hidroxi o alcoxi C1-6 y dicho alquilo o alcoxi incorpora opcionalmente un carbonilo adyacente al O o en cualquier posicion en el anillo o ii) un sistema de anillos aromáticos seleccionado de fenilo, bifenilo, naftilo o una estructura de anillo heteroaromática monocíclica o bicíclica que contiene 1 a 3 heteroátomos seleccionados, de modo independiente, de O, N y S, donde dicho sistema e anillo aromático está opcionalmente sustituido con 1 o varios sustituyentes seleccionados de halogeno, SO2R9, SO2NR9R10, OH, alquilo C1-7, alcoxi C1-7, CN, CONR2R3, NR2COR3 y COR3; donde dicho alcoxi está también opcionalmente sustituido con alcoxi C1-6 y donde dicho alcoxi incorpora opcionalmente un carbonilo adyacente al O y dicho alquilo está también opcionalmente sustituido con hidroxi o alcoxi C1-6 y dicho alquilo o alcoxi incorpora un carbonilo adyacente al O o en cualquier posicion en el alquilo; R12 representa H o halogeno o un C opcionalmente sustituido con 1 a 3 átomos de halogeno; en cada aparicion R2, R3, R4, R5, R6, R9 y R10 representan, de modo independiente, H, alquilo C1-6 o alcoxi C1-6 donde dicho alcoxi incorpora un carbonilo adyacente al O, y dicho alquilo está también opcionalmente sustituido con halogeno, alcoxi C1-6, CHO, alcanoílo C2-6, OH, CONR7R8 y NR7COR8; o los grupos NR2R3, NR4R5 y NR9R10 representan cada uno, de modo independiente, un anillo azacíclico saturado e 5 a 7 miembros que opcionalmente incorpora un heteroátomo adicional seleccionado de O, S y NR11, donde dicho anillo está también opcionalmente sustituido con halogeno, alcoxi C1-6, CHO, alcanoílo C2-6, OH, CONR7R8 y NR7COR8; en cada aparicion R7, R8 y R11 representan, de modo independiente, H o alquilo C1-6, o el grupo NR7R8 representa un anillo azacíclico saturado de 5 a 7 miembros que opcionalmente incorpora un heteroátomo adicional seleccionado de O, S y NR11; y sus sales farmacéuticamente aceptables; con la condicion de que se excluyan los compuestos 1-beta-D- ribofuranosil-2-oxopirrolo[3,2-d]pirimidin-4(3H,5H)-tiona, 1-(2,3,5-tri-O-benzoil-1-beta-D-ribofuranosil)-2-oxopirrolo[3,2-d]pirimidin-4(3H,5H)-tiona y 5,7-dimercapto-1,4,6-triazaindeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0402972A SE0402972D0 (sv) | 2004-12-06 | 2004-12-06 | Novel compounds |
| SE0501093 | 2005-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051698A1 true AR051698A1 (es) | 2007-01-31 |
Family
ID=36578191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105071A AR051698A1 (es) | 2004-12-06 | 2005-12-05 | Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US7829707B2 (es) |
| EP (1) | EP1824855B1 (es) |
| JP (1) | JP5028270B2 (es) |
| KR (3) | KR101412939B1 (es) |
| CN (1) | CN101072778B (es) |
| AR (1) | AR051698A1 (es) |
| AU (1) | AU2005312388B2 (es) |
| BR (1) | BRPI0518846B1 (es) |
| CA (1) | CA2591314C (es) |
| CY (1) | CY1113209T1 (es) |
| DK (1) | DK1824855T3 (es) |
| ES (1) | ES2390888T3 (es) |
| HR (1) | HRP20120781T1 (es) |
| IL (1) | IL183182A (es) |
| ME (1) | ME01486B (es) |
| MX (1) | MX2007006497A (es) |
| MY (1) | MY140748A (es) |
| NO (1) | NO20072399L (es) |
| NZ (1) | NZ555046A (es) |
| PL (1) | PL1824855T3 (es) |
| PT (1) | PT1824855E (es) |
| RS (1) | RS52490B (es) |
| RU (2) | RU2409578C2 (es) |
| SA (1) | SA05260385B1 (es) |
| SI (1) | SI1824855T1 (es) |
| TW (1) | TWI365189B (es) |
| UA (1) | UA89968C2 (es) |
| UY (1) | UY29246A1 (es) |
| WO (1) | WO2006062465A1 (es) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| JP5701485B2 (ja) * | 2006-02-21 | 2015-04-15 | テバ ファーマシューティカル インダストリーズ リミティド | 多系統萎縮症の治療のためのラサギリンの使用 |
| US20090286813A1 (en) * | 2006-04-13 | 2009-11-19 | Astrazeneca Ab | Thioxanthine Derivatives and Their Use as Inhibitors of MPO |
| UY30267A1 (es) * | 2006-04-13 | 2007-11-30 | Astrazeneca Ab | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| JP5201063B2 (ja) * | 2008-04-15 | 2013-06-05 | 信越化学工業株式会社 | 付加硬化型シリコーン組成物及びその硬化物 |
| SG174402A1 (en) | 2009-03-23 | 2011-10-28 | Glenmark Pharmaceuticals Sa | Fused pyrimidine-dione derivatives as trpa1 modulators |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| TWI515187B (zh) * | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
| TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| WO2013068875A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | 2-thiopyrimidinones |
| WO2013150115A1 (en) * | 2012-04-05 | 2013-10-10 | Basf Se | N- substituted hetero - bicyclic compounds and derivatives for combating animal pests |
| ES2984771T3 (es) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| HUE033848T2 (en) | 2012-06-15 | 2018-01-29 | Janssen Sciences Ireland Uc | Heterocyclic-Substituted 1,3-Dihydro-2H-Benzimidazol-2-one Derivatives as Air Giant Cell Virus Virus |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| EP3191485A1 (en) * | 2014-09-11 | 2017-07-19 | Bristol-Myers Squibb Company | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9616063B2 (en) * | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CN107531647A (zh) | 2015-05-05 | 2018-01-02 | 辉瑞大药厂 | 2‑硫代嘧啶酮类 |
| WO2017040449A1 (en) * | 2015-09-03 | 2017-03-09 | Bristol-Myers Squibb Company | Triazolopyridine inhibitors of myeloperoxidase |
| US10214527B2 (en) * | 2015-09-03 | 2019-02-26 | Bristol-Myers Squibb Company | Triazolopyridine inhibitors of myeloperoxidase |
| WO2017160632A1 (en) * | 2016-03-14 | 2017-09-21 | Bristol-Myers Squibb Company | Triazolopyridine inhibitors of myeloperoxidase |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| WO2019016074A1 (en) * | 2017-07-17 | 2019-01-24 | Astrazeneca Ab | Mpo inhibitors for use in medicine |
| WO2019078871A1 (en) | 2017-10-19 | 2019-04-25 | Texas State University | PHOTOACTIVABLE PRODRANT AGAINST CANCER |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| WO2020021300A1 (en) | 2018-07-24 | 2020-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of myeloperoxidase (mpo) inhibitors for the treatment of chemoresistant acute myeloid leukemia (aml) |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021013942A1 (en) | 2019-07-24 | 2021-01-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of myeloperoxidase inhibitors for the treatment of cardiovascular diseases in patients suffering from myeloproliferative neoplasms |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US20240067651A1 (en) * | 2019-10-10 | 2024-02-29 | Biohaven Therapeutics Ltd. | Prodrugs of myeloperoxidase inhibitors |
| PH12022550892A1 (en) | 2019-10-14 | 2023-05-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2023519662A (ja) * | 2020-03-05 | 2023-05-12 | バイオヘイブン・セラピューティクス・リミテッド | ミエロペルオキシダーゼ阻害剤を用いて筋萎縮性側索硬化症を処置する方法 |
| US20230192700A1 (en) | 2020-03-06 | 2023-06-22 | Bayer Aktiengesellschaft | Pyrazolopyrazines acting on cancers via inhibition of cdk12 |
| MX2022013788A (es) * | 2020-05-06 | 2022-11-30 | Biohaven Therapeutics Ltd | Proceso para la preparacion de verdiperstat. |
| WO2021250180A1 (en) | 2020-06-11 | 2021-12-16 | Janssen Sciences Ireland Unlimited Company | Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| CN115403584B (zh) * | 2021-05-26 | 2024-04-02 | 长春金赛药业有限责任公司 | 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| UY40399A (es) | 2022-08-18 | 2024-02-15 | Astrazeneca Ab | Inhibidores de mieloperoxidasa |
| EP4624473A1 (en) * | 2022-12-09 | 2025-10-01 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Pyrrolo[3,2-d]pyrimidin-4-one derivative, and preparation method therefor and medical use thereof |
| WO2025107036A1 (en) * | 2023-11-23 | 2025-05-30 | Syntara Limited | Dual inhibitors of amine oxidases and peroxidases, and uses thereof |
| WO2025172474A1 (en) | 2024-02-15 | 2025-08-21 | Astrazeneca Ab | Inhibitors of myeloperoxidase |
| WO2025190901A1 (en) | 2024-03-13 | 2025-09-18 | Institut National de la Santé et de la Recherche Médicale | Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135753A (en) * | 1961-05-10 | 1964-06-02 | Burroughs Wellcome Co | Alkylthiopurines and method |
| US3652579A (en) * | 1969-06-26 | 1972-03-28 | Hoffmann La Roche | 1-methyl-2-substituted 5-nitroimidazoles |
| SE7810947L (sv) | 1978-10-20 | 1980-04-21 | Draco Ab | 3-alkylxanthines |
| US4710503A (en) * | 1985-02-07 | 1987-12-01 | Euroceltique S.A. | 6-thioxanthine derivatives |
| WO1989006125A1 (en) | 1987-12-31 | 1989-07-13 | Smithkline Beckman Corporation | 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols |
| DK440989A (da) | 1988-09-12 | 1990-03-13 | Smithkline Beecham Corp | Dopamin-beta-hydroxylase inhibitorer |
| JPH02160235A (ja) | 1988-12-13 | 1990-06-20 | Konica Corp | ハロゲン化銀カラー写真画像の形成方法 |
| EP0430300A3 (en) | 1989-12-01 | 1992-03-25 | Takeda Chemical Industries, Ltd. | Xanthine derivatives, their production and use |
| US5100906A (en) | 1990-04-19 | 1992-03-31 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers |
| FR2665636B1 (fr) * | 1990-08-10 | 1994-10-07 | Adir | Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer. |
| US6046019A (en) * | 1991-07-09 | 2000-04-04 | Goumeniouk; Alexander P. | Diagnostic kits and methods for making granulocyte cell counts |
| US5281209A (en) | 1992-06-30 | 1994-01-25 | The Procter & Gamble Company | Absorbent article having tucked flaps |
| FI944933A7 (fi) | 1992-04-21 | 1994-10-20 | Biocryst Pharm Inc | 7-disubstitoitu metyyli-4-okso-3H,5H-pyrrolo(3,2-d) pyrimidiini ja sit ä sisältäviä farmaseuttisia käyttöjä ja koostumuksia |
| US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| JP2802547B2 (ja) * | 1993-11-26 | 1998-09-24 | ファイザー・インク． | 抗炎症剤としてのイソキサゾリン化合物 |
| US5489598A (en) * | 1994-06-08 | 1996-02-06 | Warner-Lambert Company | Cytoprotection utilizing aryltriazol-3-thiones |
| WO1996018400A1 (en) | 1994-12-13 | 1996-06-20 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
| US6025361A (en) * | 1994-12-13 | 2000-02-15 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
| ATE247116T1 (de) * | 1994-12-13 | 2003-08-15 | Euro Celtique Sa | Arylthioxanthine |
| US5756511A (en) * | 1995-04-03 | 1998-05-26 | Cell Therapeutics, Inc. | Method for treating symptoms of a neurodegenerative condition |
| US6294541B1 (en) * | 1996-06-06 | 2001-09-25 | Euro-Celtique S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
| GB9626643D0 (en) | 1996-12-21 | 1997-02-12 | Astra Pharma Prod | Compounds |
| US5976823A (en) * | 1997-03-19 | 1999-11-02 | Integrated Biomedical Technology, Inc. | Low range total available chlorine test strip |
| EP1016407B1 (en) | 1997-09-05 | 2006-05-10 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives for treating brain ischemia |
| AU9297798A (en) | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
| AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| US6413975B1 (en) * | 1999-04-02 | 2002-07-02 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase iv inhibition activity |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| US6319928B1 (en) * | 1998-11-30 | 2001-11-20 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
| DZ3019A1 (fr) | 1999-03-01 | 2005-05-20 | Smithkline Beecham Corp | Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd. |
| GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
| FR2811989A1 (fr) | 2000-07-18 | 2002-01-25 | Sanofi Synthelabo | Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique |
| WO2002008237A2 (en) | 2000-07-21 | 2002-01-31 | Lyles Mark B | Materials and methods for binding nucleic acids to surfaces |
| GB0100620D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| GB0100623D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| FR2819723B1 (fr) * | 2001-01-23 | 2006-11-17 | Arnaud Mainnemare | Composition halogene, son procede de preparation et ses utilisations |
| WO2002066447A1 (en) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors |
| EP1387893B1 (en) | 2001-05-08 | 2006-11-29 | AstraZeneca AB | An assay for detecting inhibitors of the enzyme myeloperokidase |
| SE0103766D0 (sv) * | 2001-11-09 | 2001-11-09 | Astrazeneca Ab | Novel assay |
| ES2193839B1 (es) * | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| KR20100056569A (ko) | 2002-01-28 | 2010-05-27 | 교와 핫꼬 기린 가부시키가이샤 | 운동성 질환에 걸린 환자의 치료 방법 |
| ES2208063B1 (es) * | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| SE0301232D0 (sv) | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
| SE0302756D0 (sv) | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
| DE602004018808D1 (de) | 2003-10-31 | 2009-02-12 | Cv Therapeutics Inc | Antagonisten des a2b-adenosinrezeptors |
| CN101863888B (zh) | 2004-02-14 | 2012-07-18 | 葛兰素史密斯克莱有限责任公司 | 具有hm74a受体活性的药物 |
| WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
| SE0402591D0 (sv) | 2004-10-25 | 2004-10-25 | Astrazeneca Ab | Novel use |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| UY30267A1 (es) | 2006-04-13 | 2007-11-30 | Astrazeneca Ab | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| JP2009539829A (ja) | 2006-06-05 | 2009-11-19 | アストラゼネカ・アクチエボラーグ | ミエロペルオキシダーゼ阻害剤としてのピロロ［３，２−ｄ］ピリミジン−４−オン誘導体 |
| AR066936A1 (es) | 2007-06-13 | 2009-09-23 | Astrazeneca Ab | 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas. |
| US20090054468A1 (en) | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
-
2005
- 2005-12-02 MY MYPI20055659A patent/MY140748A/en unknown
- 2005-12-05 ME MEP-2012-109A patent/ME01486B/me unknown
- 2005-12-05 DK DK05812036.1T patent/DK1824855T3/da active
- 2005-12-05 SA SA05260385A patent/SA05260385B1/ar unknown
- 2005-12-05 PL PL05812036T patent/PL1824855T3/pl unknown
- 2005-12-05 AU AU2005312388A patent/AU2005312388B2/en not_active Expired
- 2005-12-05 BR BRPI0518846-6A patent/BRPI0518846B1/pt active IP Right Grant
- 2005-12-05 KR KR1020137005332A patent/KR101412939B1/ko not_active Expired - Lifetime
- 2005-12-05 HR HRP20120781TT patent/HRP20120781T1/hr unknown
- 2005-12-05 AR ARP050105071A patent/AR051698A1/es unknown
- 2005-12-05 CA CA2591314A patent/CA2591314C/en not_active Expired - Lifetime
- 2005-12-05 JP JP2007544307A patent/JP5028270B2/ja not_active Expired - Lifetime
- 2005-12-05 SI SI200631433T patent/SI1824855T1/sl unknown
- 2005-12-05 UA UAA200705136A patent/UA89968C2/uk unknown
- 2005-12-05 CN CN2005800419194A patent/CN101072778B/zh not_active Expired - Lifetime
- 2005-12-05 KR KR1020137033109A patent/KR101557715B1/ko not_active Expired - Lifetime
- 2005-12-05 NZ NZ555046A patent/NZ555046A/en not_active IP Right Cessation
- 2005-12-05 PT PT05812036T patent/PT1824855E/pt unknown
- 2005-12-05 ES ES05812036T patent/ES2390888T3/es not_active Expired - Lifetime
- 2005-12-05 EP EP05812036A patent/EP1824855B1/en not_active Expired - Lifetime
- 2005-12-05 RU RU2007119307/04A patent/RU2409578C2/ru active
- 2005-12-05 MX MX2007006497A patent/MX2007006497A/es active IP Right Grant
- 2005-12-05 RS RS20120426A patent/RS52490B/sr unknown
- 2005-12-05 KR KR1020077012654A patent/KR101412786B1/ko not_active Expired - Lifetime
- 2005-12-05 UY UY29246A patent/UY29246A1/es not_active Application Discontinuation
- 2005-12-05 US US11/720,913 patent/US7829707B2/en active Active
- 2005-12-05 WO PCT/SE2005/001835 patent/WO2006062465A1/en not_active Ceased
- 2005-12-05 RU RU2010139806/04A patent/RU2577858C2/ru active
- 2005-12-06 TW TW094143007A patent/TWI365189B/zh not_active IP Right Cessation
-
2007
- 2007-05-10 NO NO20072399A patent/NO20072399L/no unknown
- 2007-05-14 IL IL183182A patent/IL183182A/en not_active IP Right Cessation
-
2010
- 2010-11-03 US US12/938,490 patent/US8859568B2/en active Active
-
2012
- 2012-10-10 CY CY20121100939T patent/CY1113209T1/el unknown
-
2014
- 2014-09-15 US US14/487,009 patent/US9580429B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051698A1 (es) | Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa | |
| AR120080A1 (es) | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos | |
| CO5140068A1 (es) | Nuevas composiciones de medicamentos a base de compuestos anticolinergicamente activos y -mimeticos | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR035804A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR076706A1 (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR051388A1 (es) | Analogos de 17-hidroxiwortmanina como inhibidores de pi3k | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| AR056197A1 (es) | Derivados de 7-metilimidazol[1,2-a]piridin-6-il-8-metil-nonamidas como inhibidores de la renina, composciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de la hipertension arterial | |
| PE20021010A1 (es) | Derivados espirociclicos como inhibidores de fosfodiesterasa-7 | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR030188A1 (es) | Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos | |
| AR063869A1 (es) | Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante | |
| ECSP045073A (es) | Nuevos derivados de piperazina | |
| CL2007001711A1 (es) | Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras. | |
| AR076263A1 (es) | Composiciones y metodos para tratar cancer. uso. | |
| AR061015A1 (es) | Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto | |
| AR031526A1 (es) | Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento. | |
| AR077525A1 (es) | 4-aril-butan-1,3-diamidas y composiciones farmaceuticas | |
| CO5590916A2 (es) | Dicetopiperacinas sustituidas como antagonistas de oxitocina | |
| AR111176A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |